iSpecimen Inc. Interest Expense
iSpecimen Inc. (ISPC) reported Interest Expense of $7.36 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-11-07
- iSpecimen Inc. interest expense for the quarter ending 2024-09-30 was $7.36K, a 64.93% increase year-over-year.
- iSpecimen Inc. interest expense for the quarter ending 2024-06-30 was $4.47K, a 26.56% increase year-over-year.
- iSpecimen Inc. interest expense for the quarter ending 2024-03-31 was $4.46K, a 26.31% increase year-over-year.
- iSpecimen Inc. interest expense for the quarter ending 2023-12-31 was $4.47K, a 95.54% decline year-over-year.
- iSpecimen Inc. interest expense for fiscal 2023 was $16.00K, a 93.30% decline from fiscal 2022.
- iSpecimen Inc. interest expense for fiscal 2022 was $238.96K, a 88.64% decline from fiscal 2021.
- iSpecimen Inc. interest expense for fiscal 2021 was $2.10M, a 0.28% increase from fiscal 2020.
- iSpecimen Inc. interest expense for fiscal 2020 was $2.10M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $7.36K 10-Q · filed 2024-11-07 | $11.84K derived: sum of 2 quarters · filed 2024-11-07 | $16.30K 10-Q · filed 2024-11-07 | $20.77K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $4.47K 10-Q · filed 2024-08-06 | $8.94K 10-Q · filed 2024-08-06 | $13.40K derived: sum of 3 quarters · filed 2024-08-06 | $17.87K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $4.46K 10-Q · filed 2024-05-07 | $8.93K derived: sum of 2 quarters · filed 2024-05-07 | $13.40K derived: sum of 3 quarters · filed 2024-11-07 | $16.93K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $4.47K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $8.93K derived: sum of 2 quarters · filed 2024-11-07 | $12.47K derived: sum of 3 quarters · filed 2024-11-07 | $16.00K 10-K · filed 2024-03-13 |
| 2023-09-30 | $4.46K 10-Q · filed 2024-11-07 | $8.00K derived: sum of 2 quarters · filed 2024-11-07 | $11.54K 10-Q · filed 2024-11-07 | $111.59K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.54K 10-Q · filed 2024-08-06 | $7.07K 10-Q · filed 2024-08-06 | $107.12K derived: sum of 3 quarters · filed 2024-08-06 | $165.71K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $3.54K 10-Q · filed 2024-05-07 | $103.59K derived: sum of 2 quarters · filed 2024-05-07 | $162.18K derived: sum of 3 quarters · filed 2024-05-07 | $204.45K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $100.05K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $158.64K derived: sum of 2 quarters · filed 2024-03-13 | $200.91K derived: sum of 3 quarters · filed 2024-03-13 | $238.96K 10-K · filed 2024-03-13 |
| 2022-09-30 | $58.59K 10-Q · filed 2023-11-02 | $100.86K derived: sum of 2 quarters · filed 2023-11-02 | $138.91K 10-Q · filed 2023-11-02 | $179.04K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $42.27K 10-Q · filed 2023-08-02 | $80.32K 10-Q · filed 2023-08-02 | $120.45K derived: sum of 3 quarters · filed 2023-08-02 | $196.38K derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $38.05K 10-Q · filed 2023-05-04 | $78.18K derived: sum of 2 quarters · filed 2023-05-04 | $154.10K derived: sum of 3 quarters · filed 2023-05-04 | $1.29M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $40.13K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $116.06K derived: sum of 2 quarters · filed 2023-03-30 | $1.25M derived: sum of 3 quarters · filed 2023-03-30 | $2.10M 10-K/A · filed 2023-03-30 |
| 2021-09-30 | $75.92K 10-Q · filed 2022-11-08 | $1.21M derived: sum of 2 quarters · filed 2022-11-08 | $2.06M 10-Q · filed 2022-11-08 | $2.64M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $1.13M 10-Q · filed 2022-08-04 | $1.99M 10-Q · filed 2022-08-04 | $2.57M derived: sum of 3 quarters · filed 2022-08-04 | $3.04M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $853.15K 10-Q · filed 2022-05-10 | $1.43M derived: sum of 2 quarters · filed 2022-05-10 | $1.90M derived: sum of 3 quarters · filed 2022-05-10 | $2.36M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $579.10K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $1.05M derived: sum of 2 quarters · filed 2022-03-22 | $1.51M derived: sum of 3 quarters · filed 2022-03-22 | $2.10M 10-K · filed 2022-03-22 |
| 2020-09-30 | $469.48K 10-Q · filed 2021-11-04 | $928.48K derived: sum of 2 quarters · filed 2021-11-04 | $1.52M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $459.00K 10-Q · filed 2021-08-10 | $1.05M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |